Tag: HCV
-
Building Capacity on Intellectual Property, Free Trade Agreement and Access to Medicines Workshop
ATL MST – ITPC MENA WORKSHOP TUNISIA 16, 17 & 18 NOVEMBER 2015 One of the most pressing issues in the 21st century is the lack of availability of essential medicines to poor patients in underdeveloped and developing countries. The problem is attributed to the existing Intellectual Property Rights (IPR) regimes, which were not aligned…
-
HCV
Hepatitis C: Hepatitis C virus (HCV), is a major health concern in MENA. A country like Egypt for example has the highest prevalence of HCV in the world. Pakistan has also a significant number of people with HCV infection. In recent years new treatment strategies have provided an opportunity to cure and eliminate HCV infection.…
-
Launch of Moroccan Generic Sofosbuvir: A Victory for the Wide-spread Use HCV Treatment in Morocco
According to the Ministry of Health, 625,000 people are infected by HCV, 1.6% of the general population of Morocco. Of those infected, 267,000 people have active chronic infection requiring treatment. Until recently, the management of HCV infection has been hampered by inadequate and costly treatments. The standard treatment involved a combination of pegylated interferon and…
-
Treatment Advocates Denounce Gilead’s Embargo against Thousands of Tunisians Suffering from HCV Infection
The Tunisian Association of Fight against STDs and AIDS (ATL Tunis) and the International Treatment Preparedness Coalition in MENA Region (ITPC-MENA) denounce the refusal of Gilead Sciences to make their drug against the Hepatitis C Virus (HCV), sofosbuvir, available to Tunisian patients. “For months, thousands of patients have been desperately waiting for access to sofosbuvir.…
-
Pharma Refuses to Ensure Access to Lifesaving Hepatitis C Treatment at Global Meeting
Bangkok, Thailand, February 28, 2014 —Thirty-eight activists from 22 countries joined forces at the first-ever Hepatitis C Virus (HCV) World Community Advisory Board (CAB) to demand equitable access to treatment for hepatitis C virus (HCV) from six multinational pharmaceutical companies. Yet AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck, and Roche refused to provide a plan for…
-
Global policy report on the prevention and control of viral hepatitis
The five viruses that cause infections of the liver are responsible for a widely prevalent and growing disease burden. No country, rich or poor, is spared. These viruses are important as they cause infectious diseases in their own right. Hepatitis A and E viruses are major foodborne and waterborne infections, which cause millions of cases…